Trial Profile
A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Metastatic Melanoma; Response Monitoring and Resistance Prediction with Positron Emission Tomography and Tumor Characteristics.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2022
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; F-18 fluorothymidine (Primary) ; Vemurafenib (Primary) ; Fludeoxyglucose F-18
- Indications Malignant melanoma
- Focus Diagnostic use; Therapeutic Use
- Acronyms REPOSIT
- 01 Feb 2024 Results assessing whether (early) PERCIST response monitoring with 18 F-FDG PET/CT is predictive for progression-free survival (PFS) in unresectable stage III or IV melanoma patients treated with BRAF/MEK inhibitor (MEKi) and to define dissemination patterns at progression with a lesion-based evaluation in direct comparison to baseline to improve our understanding of 18 F-FDG PET/CT during BRAF/MEKi, were published in the Clinical Nuclear Medicine.
- 02 Dec 2022 Status changed from recruiting to discontinued.
- 01 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.